168 related articles for article (PubMed ID: 9862327)
1. Local gene therapy with CTLA4-immunoglobulin fusion protein in experimental allergic encephalomyelitis.
Croxford JL; O'Neill JK; Ali RR; Browne K; Byrnes AP; Dallman MJ; Wood MJ; Fedlmann M; Baker D
Eur J Immunol; 1998 Dec; 28(12):3904-16. PubMed ID: 9862327
[TBL] [Abstract][Full Text] [Related]
2. Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival.
Comer RM; King WJ; Ardjomand N; Theoharis S; George AJ; Larkin DF
Invest Ophthalmol Vis Sci; 2002 Apr; 43(4):1095-103. PubMed ID: 11923251
[TBL] [Abstract][Full Text] [Related]
3. Differential requirement for CD80 and CD80/CD86-dependent costimulation in the lung immune response to an influenza virus infection.
Lumsden JM; Roberts JM; Harris NL; Peach RJ; Ronchese F
J Immunol; 2000 Jan; 164(1):79-85. PubMed ID: 10604996
[TBL] [Abstract][Full Text] [Related]
4. Porcine CTLA4-Ig lacks a MYPPPY motif, binds inefficiently to human B7 and specifically suppresses human CD4+ T cell responses costimulated by pig but not human B7.
Vaughan AN; Malde P; Rogers NJ; Jackson IM; Lechler RI; Dorling A
J Immunol; 2000 Sep; 165(6):3175-81. PubMed ID: 10975832
[TBL] [Abstract][Full Text] [Related]
5. Opposing effects of CTLA4-Ig and anti-CD80 (B7-1) plus anti-CD86 (B7-2) on experimental allergic encephalomyelitis.
Perrin PJ; Scott D; Davis TA; Gray GS; Doggett MJ; Abe R; June CH; Racke MK
J Neuroimmunol; 1996 Mar; 65(1):31-9. PubMed ID: 8642061
[TBL] [Abstract][Full Text] [Related]
6. CTLA4-Ig: a novel immunosuppressive agent.
Najafian N; Sayegh MH
Expert Opin Investig Drugs; 2000 Sep; 9(9):2147-57. PubMed ID: 11060799
[TBL] [Abstract][Full Text] [Related]
7. Antigen-presenting T cells induce the development of cytotoxic CD4+ T cells. I. Involvement of the CD80-CD28 adhesion molecules.
Mauri D; Wyss-Coray T; Gallati H; Pichler WJ
J Immunol; 1995 Jul; 155(1):118-27. PubMed ID: 7541409
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of expression of costimulatory molecules and their ligands in murine relapsing experimental autoimmune encephalomyelitis in vivo.
Issazadeh S; Navikas V; Schaub M; Sayegh M; Khoury S
J Immunol; 1998 Aug; 161(3):1104-12. PubMed ID: 9686568
[TBL] [Abstract][Full Text] [Related]
9. Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis.
Perrin PJ; Scott D; Quigley L; Albert PS; Feder O; Gray GS; Abe R; June CH; Racke MK
J Immunol; 1995 Feb; 154(3):1481-90. PubMed ID: 7529805
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of corneal allograft reaction by CTLA4-Ig.
Hoffmann F; Zhang EP; Pohl T; Kunzendorf U; Wachtlin J; Bulfone-Paus S
Graefes Arch Clin Exp Ophthalmol; 1997 Aug; 235(8):535-40. PubMed ID: 9285225
[TBL] [Abstract][Full Text] [Related]
11. Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis.
Hurwitz AA; Sullivan TJ; Krummel MF; Sobel RA; Allison JP
J Neuroimmunol; 1997 Mar; 73(1-2):57-62. PubMed ID: 9058759
[TBL] [Abstract][Full Text] [Related]
12. Topical CTLA4-Ig suppresses ongoing mucosal immune response in presensitized murine model of allergic rhinitis.
Sato J; Asakura K; Murakami M; Uede T; Kataura A
Int Arch Allergy Immunol; 1999 Jul; 119(3):197-204. PubMed ID: 10436391
[TBL] [Abstract][Full Text] [Related]
13. Immune suppression in cynomolgus monkeys by XPro9523: an improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn.
Bernett MJ; Chu SY; Leung I; Moore GL; Lee SH; Pong E; Chen H; Phung S; Muchhal US; Horton HM; Lazar GA; Desjarlais JR; Szymkowski DE
MAbs; 2013; 5(3):384-96. PubMed ID: 23549103
[TBL] [Abstract][Full Text] [Related]
14. Suppressive effects of CTLA4-Ig on nasal allergic reactions in presensitized murine model.
Sato J; Asakura K; Murakami M; Uede T; Kataura A
Life Sci; 1999; 64(9):785-95. PubMed ID: 10075111
[TBL] [Abstract][Full Text] [Related]
15. Role of CD80, CD86, and CTLA4 on mouse CD4(+) T lymphocytes in enhancing cell-cycle progression and survival after activation with PMA and ionomycin.
Mukherjee S; Maiti PK; Nandi D
J Leukoc Biol; 2002 Nov; 72(5):921-31. PubMed ID: 12429713
[TBL] [Abstract][Full Text] [Related]
16. B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4.
Mandelbrot DA; Oosterwegel MA; Shimizu K; Yamada A; Freeman GJ; Mitchell RN; Sayegh MH; Sharpe AH
J Clin Invest; 2001 Apr; 107(7):881-7. PubMed ID: 11285307
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune arthritis.
Quattrocchi E; Dallman MJ; Feldmann M
Arthritis Rheum; 2000 Aug; 43(8):1688-97. PubMed ID: 10943858
[TBL] [Abstract][Full Text] [Related]
18. IFN-gamma-activated primary murine astrocytes express B7 costimulatory molecules and prime naive antigen-specific T cells.
Nikcevich KM; Gordon KB; Tan L; Hurst SD; Kroepfl JF; Gardinier M; Barrett TA; Miller SD
J Immunol; 1997 Jan; 158(2):614-21. PubMed ID: 8992975
[TBL] [Abstract][Full Text] [Related]
19. Co-administration of adenovirus vector expressing CTLA4-Ig prolongs transgene expression in the brain of mice sensitized with adenovirus.
Uchida T; Kajiwara K; Ideguchi M; Yoshikawa K; Morioka J; Suzuki M
Brain Res; 2001 Apr; 898(2):272-80. PubMed ID: 11306013
[TBL] [Abstract][Full Text] [Related]
20. Antiviral immune responses in CTLA4 transgenic mice.
Zimmermann C; Seiler P; Lane P; Zinkernagel RM
J Virol; 1997 Mar; 71(3):1802-7. PubMed ID: 9032309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
